Literature DB >> 27235991

Academic physicians' and medical students' perceived barriers toward bystander administered naloxone as an overdose prevention strategy.

Amanda K Gatewood1, Michael J Van Wert2, Andrew P Andrada2, Pamela J Surkan2.   

Abstract

AIMS: To identify perceived barriers to the prescription of naloxone to third-party contacts of opiate users.
DESIGN: Qualitative descriptive study.
SETTING: Two academic hospitals in Baltimore, MD, USA. PARTICIPANTS: Thirty medical providers, including both physicians and medical students. MEASUREMENTS: Qualitative; in-depth interviews and focus groups analyzed using line-by-line, focused, and axial coding based on methods adapted from grounded theory.
FINDINGS: Academic physicians and medical students cited three categories of barriers to naloxone prescription related to drug, provider, and patient characteristics. Concerns about naloxone itself included inability to prevent addictive behaviors, duration of action, medical risks, expiration date, and route of administration. Concerns about medical providers included lack of knowledge or experience, medical community common practices and norms, insufficient provision of third-party education, physician and clinic scheduling practices, worry about insulting patients, and fear of being viewed as enabling drug abuse. Concerns about patients included increased risk-taking behaviors, opiate withdrawal symptoms, potential repeat overdose related to withdrawal-discomfort, decreased contact with medical providers, and stigma.
CONCLUSIONS: Minimizing barriers to naloxone provision may increase acceptability and prescription practice in the medical community. Addressing these barriers from multiple provider perspectives is critical to advance naloxone prescription as a harm reduction strategy, which has the potential to prevent opiate overdoses.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Harm reduction; Naloxone; Naloxone prescription; Opioid overdose; Overdose prevention

Mesh:

Substances:

Year:  2016        PMID: 27235991     DOI: 10.1016/j.addbeh.2016.05.013

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  7 in total

1.  Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.

Authors:  Lisa R Gerak; David R Maguire; James H Woods; Stephen M Husbands; Alex Disney; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2018-11-21       Impact factor: 4.030

2.  Making Naloxone Rescue Part of Basic Life Support Training for Medical Students.

Authors:  Helen E Jack; Katherine E Warren; Sivakumar Sundaram; Galina Gheihman; John Weems; Ali S Raja; Emily S Miller
Journal:  AEM Educ Train       Date:  2018-03-30

Review 3.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

Authors:  Bertha K Madras; N Jia Ahmad; Jenny Wen; Joshua Sharfstein Sharfstein
Journal:  NAM Perspect       Date:  2020-04-27

4.  Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review.

Authors:  Emily Behar; Rita Bagnulo; Phillip O Coffin
Journal:  Prev Med       Date:  2018-06-15       Impact factor: 4.018

5.  Evaluation of an interprofessional naloxone didactic and skills session with medical residents and physician assistant learners.

Authors:  Daniel Hargraves; Christopher C White; Marcia R Mauger; Aruna Puthota; Harini Pallerla; Patricia Wigle; Sarah L Brubaker; Jeffrey D Schlaudecker
Journal:  Pharm Pract (Granada)       Date:  2019-09-12

Review 6.  Perspectives of Stakeholders of Equitable Access to Community Naloxone Programs: A Literature Review.

Authors:  Lucas Martignetti; Winnie Sun
Journal:  Cureus       Date:  2022-01-20

7.  If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.

Authors:  Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Alexander Y Walley; Robin A Pollini
Journal:  BMC Public Health       Date:  2022-04-13       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.